English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, September 28, 2023
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
Monday, September 25, 2023
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
Thursday, September 21, 2023
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
Tuesday, September 12, 2023
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem
Thursday, July 20, 2023
エーザイ、「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023(AAIC2023)において発表
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Wednesday, July 12, 2023
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research
Friday, July 7, 2023
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
エーザイとバイオジェン・インク、「LEQEMBI(R)」(レカネマブ)がアルツハイマー病治療薬として米国FDAよりフル承認を取得
Friday, June 30, 2023
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575